
People living with rarer types of cystic fibrosis will pay a fraction of the price to access life-changing treatment under an expansion of the Pharmaceutical Benefits Scheme.
The changes will take effect from July, and mean the drug Trikafta will be affordable for patients diagnosed with rarer mutations of the disease, thanks to government subsidies.